http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
-
Alnylam Pharma (ALNY) Presents New Long-Term Results from Global Open-Label Extension Study of ONPATTRO at EAN
-
Alnylam Presents New Long-Term Results from Global Open-Label Extension Study of ONPATTRO® (patisiran) at the European Academy of Neurology Virtual Congress 2020
-
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
-
Alnylam Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Period Activity
-
Vir Biotechnology (VIR), Alnylam Pharma (ALNY) Report Selection of Development Candidate for VIR-2703, Targeting SARS-CoV-2 for Treatment of COVID-19
-
Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19
-
Alnylam to Webcast Conference Call Discussing First Quarter 2020 Financial Results
-
Alnylam Pharma (ALNY) Announces Fast Track Designation for Vutrisiran for Treatment of Polyneuropathy of hATTR Amyloidosis
-
Alnylam Receives Fast Track Designation for Vutrisiran for the Treatment of the Polyneuropathy of hATTR Amyloidosis
-
Alnylam to Webcast Presentation at 19th Annual Needham Virtual Healthcare Conference
-
Blackstone (BX) and Alnylam (ALNY) Enter $2 Billion Agreement to Accelerate Advancement of RNAi Therapeutics
-
Blackstone and Alnylam Enter Into $2 Billion Strategic Financing Collaboration to Accelerate the Advancement of RNAi Therapeutics
-
Vir Biotechnology (VIR) and Alnylam (ALNY) Expand Collaboration to Advance Investigational RNAi Therapeutics Targeting Treatment of COVID-19
-
Vir and Alnylam Expand Collaboration to Advance Investigational RNAi Therapeutics Targeting Host Factors for the Treatment of COVID-19
-
Vir (VIR) and Alnylam (ALNY) Expand Collaboration to Advance RNAi Therapeutics for Treatment of Coronavirus Infection, Including COVID-19
-
Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19
-
Alnylam Announces Changes to its Board of Directors
-
Alnylam Announces Approval in Brazil of ONPATTRO® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
-
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
-
Alnylam to Webcast Presentation at 9th Annual SVB Leerink Global Healthcare Conference
-
Alnylam Pharma (ALNY) Reports Complete Enrollment of HELIOS-A Phase 3 Study of Vutrisiran for Treatment of hATTR Amyloidosis with Polyneuropathy
-
Alnylam Completes Enrollment of HELIOS-A Phase 3 Study of Vutrisiran for the Treatment of hATTR Amyloidosis with Polyneuropathy
-
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period Activity
-
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Financial Results
-
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2019 Global Net Product Revenues and Provides Additional Commercial Updates
-
Alnylam Pharma (ALNY) Initiates Rolling Submission of NDA to FDA for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
-
Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
-
Alnylam to Webcast Presentation at 38th Annual J.P. Morgan Healthcare Conference
-
Alnylam Pharma (ALNY) ILLUMINATE-A Phase 3 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1 Met Its Primary Endpoint
-
Alnylam Reports Positive Topline Results from ILLUMINATE-A Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1
-
Alnylam to Webcast Presentations at Upcoming December Investor Conferences
-
Alnylam Pharma (ALNY) Announces 2020 Product, Pipeline Goals and Provides Updates at R&D Day
-
Alnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day
-
Alnylam Pharma (ALNY) Plans New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI
-
Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI™ (givosiran)
-
Alnylam Pharma (ALNY) Confirms Approval of GIVLAARI by FDA
-
Alnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA)
-
Alnylam Announces Second Annual Advocacy for Impact Grants Program
-
Alnylam to Webcast Presentation at Stifel 2019 Healthcare Conference
-
Alnylam Pharma (ALNY) Begins ILLUMINATE-C Ph. 3 Study of Lumasiran; Reports New Positive Results from Phase 2 Open-Label Extension Study
-
Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
-
Alnylam Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Period Activity
-
Alnylam Named #1 Biopharma Employer by Science Magazine
-
Alnylam to Webcast Conference Call Discussing Third Quarter 2019 Financial Results
-
Alnylam’s Distinguished Chemist Mano Manoharan Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
-
Alnylam Pharma (ALNY) Reports Filing for Marketing Authorization of ONPATTRO (patisiran) in Brazil for Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
-
Alnylam Announces Filing for Marketing Authorization of ONPATTRO® (patisiran) in Brazil for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
-
Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference
-
Alnylam Pharma (ALNY) Commences APOLLO-B Phase 3 Study of Patisiran
